Supplementary Figure S2 from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort

Supplementary Figure 2: MHC-I and MHC-II expression is higher in Stage I/II, premenopausal patients. The relative frequency difference of tumors having (A) high MHC-I expression and (B) ≥ 5% tumor cells expressing MHC-II are compared between stage and menopausal status . Relative frequency difference calculated using Stage I/II and premenopausal as control condition, with negative RFD representing frequency higher in Stage I/II or premenopausal patients. Bootstrap method used to generate standard errors.